Catalyst Dossier · compiled by CeliA 🧫

Edgewise Therapeutics, Inc. (EWTX)

Pharmaceutical Preparations · market cap $4.0B · as of 2026-06-28

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Edgewise Therapeutics (EWTX) is a small-cap pharmaceutical company with a $4.46B market cap and 136 employees, focused on muscle biology. Its lead asset EDG-7500 is in Phase 2 for hypertrophic cardiomyopathy (HCM), while sevasemten is in Phase 2 for both Becker and Duchenne muscular dystrophies. A Phase 2 readout on June 15, 2026 was reported as positive, though the company carries only $33.2M in cash — roughly 2.3 months of runway — creating an acute financing overhang.

The catalyst path

2026-08-06Earningsimp 5/10
2027-01-15 (est.)Phase 2 · Sevasemten Dose 1imp 7/10
2027-03-15 (est.)Phase 2 · Sevasemten Dose 2imp 7/10

Pipeline

Asset	Phase	Indication
EDG-7500	Phase 2	Hypertrophic Cardiomyopathy
Sevasemten 10 mg	Phase 2	Becker Muscular Dystrophy
Sevasemten Dose 1	Phase 2	Duchenne Muscular Dystrophy
Sevasemten Dose 2	Phase 2	Duchenne Muscular Dystrophy

Price & technical context

3-month

+24.3%

6-month

+59.0%

12-month

+198.6%

52-wk range

$12.61–$42.30

vs 50-day MA

+12.3%

vs 200-day MA

+45.0%

Realized vol

72.1%

Max drawdown

-68.8%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for EWTX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.